GRM2 and psychiatric disorder: Although mGluR2/3 agonists are not approved for use in humans, a related mechanism can be targeted with NAC, which is available over the counter, is well-tolerated, and has shown efficacy in clinical trials treating a variety of substance use and psychiatric disorders [64, 65].